Skip to main content

Table 5 PCT and the incidence of cancer

From: Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study

Cancer subtype

All subjects

Men

Women

N

HRa

P b

N

HRa

P c

N

HRa

P c

(95% CI)

(95% CI)

(95% CI)

Total cancer incidence

520

1.02 (0.93 to 1.12)

0.611

257

1.08 (0.96 to 1.21)

0.184

263

0.97 (0.86 to 1.11)

0.705

Colon

36

1.18 (0.90 to 1.55)

0.238

19

1.49 (1.13 to 1.95)

0.005**

17

0.59 (0.31 to 1.13)

0.108

Rectum

34

1.16 (0.86 to 1.57)

0.343

15

1.14 (0.71 to 1.83)

0.583

19

1.15 (0.79 to 1.67)

0.469

Lung and bronchi

43

0.95 (0.68 to 1.33)

0.764

23

0.95 (0.62 to 1.46)

0.819

20

0.96 (0.59 to 1.54)

0.864

Urinary tract

36

0.87 (0.59 to 1.27)

0.467

22

0.86 (0.55 to 1.35)

0.515

14

0.93 (0.52 to1.68)

0.815

Malignant melanoma

22

1.00 (0.64 to 1.57)

0.999

14

1.17 (0.74 to 1.87)

0.499

8

0.64 (0.26 to 1.62)

0.348

Skin (excluding melanoma)

29

0.88 (0.65 to 1.45)

0.879

19

1.12 (0.74 to 1.70)

0.600

10

0.59 (0.25 to 1.38)

0.225

Prostate

   

130

1.02 (0.86 to 1.21)

0.841

   

Breast

      

122

1.00 (0.83 to 1.20)

0.998

  1. aExpressed per 1 SD increment. Cox regression analysis adjusted for age and sexb or agec. CI, confidence interval; HR, hazard ratio; PCT, procalcitonin. **P <0.01.